Anti-cancer Activity of Anthricin through Caspase-dependent Apoptosis in Human Hypopharyngeal Squamous Carcinoma Cell.
10.11620/IJOB.2016.41.4.183
- Author:
Won Gi KIM
1
;
Seul Ah LEE
;
Sung Min MOON
;
Jin Soo KIM
;
Su Gwan KIM
;
Yong Kook SHIN
;
Do Kyung KIM
;
Chun Sung KIM
Author Information
1. Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University, 375 Seosuk-dong, Dong-gu, Gwangju, 501-759, Republic of Korea.
- Publication Type:Original Article
- Keywords:
Oral cancer;
Anthricin;
Deoxyphodophyllotoxin;
Apoptosis
- MeSH:
Apoptosis*;
Carcinoma, Squamous Cell*;
Caspase 3;
Cell Death;
Cell Survival;
Humans*;
Mouth Neoplasms;
Pancreatic Neoplasms;
Prostatic Neoplasms
- From:International Journal of Oral Biology
2016;41(4):183-190
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Anthricin (Deoxypodophyllotoxin), a naturally occurring flavolignan, has well known anti-cancer properties in several cancer cells, such as prostate cancer, cervical carcinoma and pancreatic cancer. However, the effects of Anthricin are currently unknown in oral cancer. We examined the anti-cancer effect and mechanism of action of Anthricin in human FaDu hypopharyngeal squamous carcinoma cells. Our data showed that Anthricin inhibits cell viability in a dose- and time-dependent manner (IC50 50 nM) in the MTT assay and Live & Dead assay. In addition, Anthricin treated FaDu cells showed marked apoptosis by DAPI stain and FACS. Furthermore, Anthricin activates anti-apoptotic factors such as caspase-3, -9 and poly (ADP-ribose) polymerase (PARP), suggesting that caspase-mediated pathways are involved in Anthricin-induced apoptosis. Anthricin treatment also leads to accumulation of the pro-apoptotic factor Bax, followed by inhibition of cell growth. Taken together, these results indicate that Anthricn-induced cell death of human FaDu hypopharyngeal squamous carcinoma cells is mediated by mitochondrial-dependent apoptotic pathway. In summary, our findings provide a framework for further exploration on Anthricin as a novel chemotherapeutic drug for human oral cancer.